

Title (en)
Multi-particle pharmaceutical formulation for colon absorption

Title (de)
Pharmazeutische Mehrfachpartikelformulierung zur Kolonabsorption

Title (fr)
Formulation pharmaceutique multiparticules pour absorption du colon

Publication
EP 2371356 A1 20111005 (EN)

Application
EP 10002656 A 20100312

Priority
EP 10002656 A 20100312

Abstract (en)
Multi-particulate pharmaceutical composition, the particles having a particle size of between 2.2 and 4 mm, preferably 2.5 to 3.1 mm and most preferably about 2.8 mm, each particle comprising: (a) a core containing or carrying at least one pharmaceutically active agent; and (b) at least one layer showing adhesion and/or being crushable in the colon comprising (i) one or more poly(meth)acrylates, and (ii) non-porous inert lubricant, selected from the group consisting of stearates, kaolin, pharmaglass, talcum and mixtures thereof.

IPC 8 full level
A61K 9/16 (2006.01); **A61K 9/50** (2006.01); **A61K 31/485** (2006.01)

CPC (source: EP US)
A61K 9/1676 (2013.01 - EP US); **A61K 9/5078** (2013.01 - EP US); **A61P 25/04** (2017.12 - EP); **A61K 9/5026** (2013.01 - EP US)

Citation (applicant)
• WO 02060415 A1 20020808 - ROEHM GMBH [DE], et al
• EP 1248599 B1 20071205 - EVONIK ROEHM GMBH [DE]
• WO 2006102446 A2 20060928 - SANDOZ AG [CH], et al
• US 6039975 A 20000321 - SHAH NAVNIT HARGOVINDAS [US], et al
• WO 2009036812 A1 20090326 - EVONIK ROEHM GMBH [DE], et al
• COUPE A.J.; DAVIS S.S.; WILDING I.R.: "Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects", PHARM. RES., vol. 8, 1991, pages 360
• FRIEND D. R.: "Oral colon-specific drug delivery", 1992, CRC PRESS INC.
• HARDY J.G.; WILSON C. G.; WOOD E.: "Drug Delivery to the proximal colon", J PHARM PHARMACOL., vol. 12, 1985, pages 874 - 7, XP000576248
• MALAGELADA J.R.: "Quantification of gastric solid-liquid discrimination during digestion of ordinary meals", GASTROENTEROLOGY, vol. 72, 1977, pages 1264 - 1267
• SHORE P.A.; BRODIE B. B.; HOGBEN, C. A.M.: "The gastric secretion of drugs : a pH partition hypothesis", JPHARMAC. EXP. THER., vol. 119, 1957, pages 361 - 369

Citation (search report)
• [X] AU 2006200783 A1 20060323 - MUNDIPHARMA MEDICAL GMBH
• [X] US 2002193445 A1 20021219 - BERTELSEN POUL [DK], et al
• [X] US 2003152627 A1 20030814 - BECKERT THOMAS [DE], et al
• [X] WO 9822096 A1 19980528 - PROCTER & GAMBLE [US]
• [X] EP 1203590 A1 20020508 - DAINIPPON PHARMACEUTICAL CO [JP]
• [X] US 6458389 B1 20021001 - DEBREGEAS PATRICE [FR], et al
• [X] WO 2004039357 A1 20040513 - ROEHM GMBH [DE], et al
• [X] US 5643602 A 19970701 - ULMIUS JAN [SE]

Cited by
WO2012052169A3

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

Designated extension state (EPC)
AL BA ME RS

DOCDB simple family (publication)
EP 2371356 A1 20111005; EP 2371356 B1 20121219; US 2012328707 A1 20121227; WO 2011110344 A1 20110915

DOCDB simple family (application)
EP 10002656 A 20100312; EP 2011001178 W 20110310; US 201113582680 A 20110310